SequelSEC

NEKTAR THERAPEUTICS NKTR

Pharmaceutical Preparations · CIK 0000906709 · Fiscal year ends 1231

AnnualQuarterlyTTM
Revenue
$10.13M
Fiscal year ended 2026-06-30
Operating income
-$42.34M
Fiscal year ended 2026-06-30
Free cash flow
-$75.86M
Fiscal year ended 2026-06-30

NEKTAR THERAPEUTICS (NKTR) reported revenue of $10.13M and net income of -$40.62M for the fiscal year ended 2026-06-30. This page shows 10 annual periods of income statement, balance sheet and cash flow figures normalized from NEKTAR THERAPEUTICS’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Pharmaceutical Preparations.

Income

NEKTAR THERAPEUTICS income by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-312024-09-302024-06-302024-03-31
Revenue$10.13M$10.86M$21.81M$11.79M$11.18M$10.46M$29.18M$24.12M$23.49M$21.64M
Cost of revenueUnavailableUnavailable$0$0$0$0$7.98M$4.44M$9.74M$8.53M
Gross profitUnavailableUnavailable$21.81M$11.79MUnavailableUnavailable$21.20M$19.69M$13.75M$13.10M
Operating income-$42.34M-$39.05M-$27.66M-$31.67M-$36.23M-$44.54M$14.35M-$34.34M-$49.77M-$35.43M
Net income-$40.62M-$44.90M-$36.08M-$35.52M-$41.59M-$50.88M$7.26M-$37.06M-$52.36M-$36.80M
Research & development$39.13M$35.68M$29.71M$27.25M$29.89M$30.48M$28.74M$35.03M$29.72M$27.41M
Weighted-average diluted sharesshares 33.05Mshares 24.74MUnavailableshares 18.95Mshares 14.09Mshares 14.06MUnavailableshares 13.95Mshares 13.92Mshares 194.75M
Pretax income-$40.30M-$43.09M-$34.70M-$35.02M-$39.40M-$46.37M$7.00M-$37.05M-$52.32M-$36.84M
Income tax expense$2.00K$64.00K$31.00K-$33.00K-$188.00K$52.00K-$259.00K$9.00K$46.00K-$35.00K
Diluted EPS$-1.23$-1.82Unavailable$-1.87$-2.95$-3.62Unavailable$-2.66$-3.76$-0.19
Selling, general & administrativeUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
General & administrative$12.76M$13.44M$11.18M$16.07M$17.07M$24.35M$17.14M$18.96M$20.51M$20.15M
Selling & marketingUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable

Balance

NEKTAR THERAPEUTICS balance by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-312024-09-302024-06-302024-03-31
Cash & equivalents$39.27M$149.58M$15.12M$41.03M$42.99M$38.89M$44.25M$30.11M$27.94M$48.64M
Total assets$1.10B$763.27M$280.41M$301.35M$207.53M$256.24M$303.85M$307.97M$343.33M$396.01M
Current assets$739.40M$589.04M$266.27M$281.36M$186.57M$229.91M$261.29M$286.48M$295.19M$319.84M
Total liabilities$192.01M$187.06M$190.57M$216.26M$231.74M$242.50M$243.11M$259.08M$263.65M$269.31M
Current liabilities$70.98M$57.71M$53.54M$66.34M$71.39M$70.93M$61.40M$67.58M$57.33M$52.41M
Total equity incl. NCI$903.12M$576.22M$89.83M$85.09M-$24.21M$13.74M$60.74M$48.88M$79.69M$126.70M
Temporary (mezzanine) equityUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
InventoryUnavailableUnavailable$0UnavailableUnavailableUnavailable$0$0$14.46M$16.24M
Accounts receivableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable$0$0$1.20M$3.62M
GoodwillUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Long-term debtUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Accounts payable$24.89M$10.03M$10.77M$15.56M$14.28M$17.83M$11.56M$8.58M$6.48M$8.76M

Cash flow

NEKTAR THERAPEUTICS cash flow by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-312024-09-302024-06-302024-03-31
Operating cash flow-$75.77M-$44.30M-$64.96M-$48.76M-$45.74M-$49.05M-$46.19M-$43.93M-$37.70M-$47.89M
Capital expenditures$94.00K$18.00K$18.00K$114.00K$37.00K$2.00K$459.00K$666.00K$186.00K$157.00K
Investing cash flow-$399.11M-$350.79M$372.00K-$94.87M$49.62M$43.69M$60.21M$46.12M$16.98M$19.26M
Financing cash flow$364.57M$529.55M$38.67M$141.68M$211.00K$7.00K$83.00K$13.00K$19.00K$42.00M
Net change in cash-$110.31M$134.46M-$25.92M-$1.96M$4.09M-$5.36M$14.14M$2.17M-$20.70M$13.36M
Stock-based compensationUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Common dividends paidUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Common share repurchasesUnavailableUnavailable$0$0$0$0$0$0$0$3.00M
Depreciation & amortization$156.00K$151.00K$190.00K$196.00K$214.00K$426.00K$332.00K$993.00K$1.46M$1.61M

Derived

NEKTAR THERAPEUTICS derived by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-312024-09-302024-06-302024-03-31
Free cash flow-$75.86M-$44.32M-$64.98M-$48.88M-$45.78M-$49.06M-$46.65M-$44.60M-$37.89M-$48.04M
Gross marginUnavailableUnavailable100.0%100.0%UnavailableUnavailable72.7%81.6%58.5%60.6%
Operating margin-417.9%-359.6%-126.9%-268.6%-324.2%-425.8%49.2%-142.4%-211.9%-163.7%
FCF margin-748.8%-408.0%-298.0%-414.5%-409.6%-469.0%-159.9%-184.9%-161.3%-222.0%
SBC / revenueUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Current ratio10.42x10.21x4.97x4.24x2.61x3.24x4.26x4.24x5.15x6.10x
Revenue YoY growth-9.3%3.8%-25.3%-51.1%-52.4%-51.7%22.1%-0.1%14.6%0.2%
Net margin-401.0%-413.4%-165.4%-301.3%-372.2%-486.4%24.9%-153.6%-222.9%-170.1%
R&D / revenue386.2%328.5%136.2%231.1%267.4%291.4%98.5%145.2%126.5%126.7%
CapEx / revenue0.9%0.2%0.1%1.0%0.3%0.0%1.6%2.8%0.8%0.7%
Long-term debt / equityUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Effective tax rateUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable-3.7%UnavailableUnavailableUnavailable

Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open NKTR in the interactive workspace to inspect any figure back to its filing.

Source filings

10-Q · Filed 2026-08-14View SEC filing
10-Q · Filed 2026-05-08View SEC filing
10-K · Filed 2026-03-13View SEC filing
10-Q · Filed 2025-11-07View SEC filing
10-Q · Filed 2025-08-08View SEC filing
10-Q · Filed 2025-05-09View SEC filing

Companies in the same industry

Reconciliation checks needing review

2 periods on this page do not reconcile under this site’s normalization. Read that as a limitation here before an observation about the company: the figures are the filer’s own, the filings linked above are authoritative, and a difference usually means the concepts this site selected do not match how this filer presents its statements. Nothing is adjusted to make a check pass.

gross profit bridgeinconsistent2025-06-30

Withheld: gross profit could not be reconciled with the rest of this filer’s statement.

gross profit bridgeinconsistent2025-03-31

Withheld: gross profit could not be reconciled with the rest of this filer’s statement.